Skip to Main Content

Paper Details

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
Leukemia
2
2023
AML, AML cells, AML xenograft models, CRISPR-, CRISPR-edited AML cells, Cas9, FLT3, HDAC, Menin, NPM1, NPM1 mutation, RNA, WEE1, WEE1 tyrosine kinase, adavosertib, cytarabine, exportin-1, mtNPM1, mutant NPM1, pan, panobinostat, patients, selinexor, tyrosine
Author NameAffiliation
Courtney D DiNardoThe University of Texas M.D. Anderson Cancer Center
Gerard M McGeehanSyndax Pharmaceuticals
Hagop KantarjianThe University of Texas M.D. Anderson Cancer Center
  • 1 - 3

Datasets

Release 1.2